NCT07419334
招募中
3 期
A Phase 3 Multicenter, Double-Masked, Randomized, Placebo-Controlled Study to Investigate the Safety, Tolerability, and Efficacy of Gildeuretinol Acetate (ALK 001) on the Progression of Stargardt Disease (STGD)
概览
- 阶段
- 3 期
- 状态
- 招募中
- 入组人数
- 230
- 试验地点
- 1
- 主要终点
- Annualized growth rate of retinal atrophic lesions measured by Fundus Autofluorescence
概览
简要总结
This study evaluates the efficacy and safety of investigational study drug ALK-001 in participants 8 to 45 years of age, inclusive, with symptoms and signs of autosomal recessive Stargardt disease (STGD)
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 8 Years 至 45 Years（Child, Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female, 8 to 45 years of age (inclusive) on the day of screening.
- •Female participants of childbearing potential, as well as fertile male participants with female partners of childbearing potential, must be willing to comply with the protocol-defined methods of contraception from the time of consent until 90 days and 30 days, respectively, after the last dose of IMP.
- •Have a clinical diagnosis of typical autosomal recessive STGD macular dystrophy
- •Have provided a genetic report by any regional accredited organization that provides certified testing indicating the presence of disease-causing mutation.
- •Have signed and dated the informed consent forms (ICFs; or assent as appropriate) to participate.
排除标准
- •Has taken disallowed items (supplements containing vitamin A or beta-carotene, liver-based products, or prescription oral retinoid medications) within 30 days of randomization.
- •Is lactating, pregnant, or has a positive serum or urine pregnancy test at screening or at randomization, or is planning to become pregnant during the course of study. A male participant who wishes to father a child during the course of the study.
- •Has ever participated in any gene therapy, cell therapy, or device study to treat STGD, unless documented confirmation of participation in the placebo arm with no surgery is provided. Has participated in a drug study to treat STGD within the past 6 months.
- •Has participated in any drug study to treat any other condition within 5 half-lives of the investigational drug prior to screening, unless documented confirmation of participation in the placebo arm is provided. Has participated in an investigational device study within 30 days prior to screening or longer if, in the Investigator's judgment, the device could affect study outcomes.
- •Anticipates participating in any other drug or device study within the duration of the study.
研究组 & 干预措施
Active
Active Comparator
干预措施: ALK-001 (Drug)
Placebo
Placebo Comparator
干预措施: Placebo (Drug)
结局指标
主要结局
Annualized growth rate of retinal atrophic lesions measured by Fundus Autofluorescence
时间窗: Month 6 to Month 24
Annualized growth rate of retinal atrophic lesions measured by Fundus Autofluorescence
次要结局
- Changes in Low Luminance Visual Acuity from baseline to Month 24(baseline to Month 24)
研究者
研究点 (1)
Loading locations...
相似试验
招募中
3 期
to Evaluate the Efficacy and Safety of KLH-2109 in Patients With Uterine Fibroids and MenorrhagiaNCT07378098JW Pharmaceutical254
招募中
不适用
A Study of AK138D1 in Advanced Malignant TumorsNCT07281326Akeso200
尚未招募
2 期
Safety and Efficacy of PSMA-Targeted Fluorescent Contrast Agent DGPR1008 for Intraoperative Imaging in Robot-Assisted Radical ProstatectomyNCT07415135Zhu Yinjie18
尚未招募
不适用
Vorasidenib Study in Pediatric Participants With Grade 2 Astrocytoma or Oligodendroglioma With an IDH1 or IDH2 MutationNCT07286292Institut de Recherches Internationales Servier (I.R.I.S.)10
尚未招募
不适用
A Study of DB-1324 in Advanced/Metastatic Gastrointestinal TumorsNCT07263594DualityBio Inc.127